Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

In the past few years, pharmaceutical companies have produced a class of drugs that lower cholesterol by inhibiting a protein called PCSK9 in a new attempt to reduce the risk of heart disease, the ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...

While the efficiency of PCSK9 mAbs, mipomersen and lomitapide has been demonstrated in FH patients, there has been no completed trial with new CETP inhibitors in FH, but one trial is underway ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol ...

Since 2019, PCSK9i have had a label expansion; positive results from major outcomes trials and large studies showing the use of PCSK9 inhibitors reducing cardiac events; a 60% price reduction on ...

Lerodalcibep is a novel, adnectin-based, small protein-binding, third-generation PCSK9 inhibitor, with long-ambient stability, developed as a more patient-friendly, once-monthly, self-administered ...